Richard Shelby actually said...

Unfortunately, Dodd-Frank provides little guidance on exactly which firms should be designated for systemic risk regulation.

I believe the need for an entity to straddle the world's research and industry is clear.

I support Federal investment in basic biomedical research and development.

As research becomes more expensive and private capital dries up, I believe it's critical to ensure support for translational research.